Ags-009 (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 49 | Systemic lupus erythematosus | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00960362 (ClinicalTrials.gov) | July 2009 | 14/8/2009 | An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE) | A Randomised, Double-blind, Placebo-controlled, and Single Dose-escalation Trial of AGS-009 Administered in Subjects With Systemic Lupus Erythematosus | Inflammation;Systemic Lupus Erythematosus (SLE) | Drug: AGS-009;Drug: placebo | Argos Therapeutics | NULL | Completed | 18 Years | 65 Years | Both | 13 | Phase 1 | United States;Sweden |